

## Onglyza<sup>®</sup> (saxagliptin) – First-time generic

- On August 1, 2023, Viartis launched an [AB-rated](#) generic version of AstraZeneca's [Onglyza \(saxagliptin\)](#) tablets.
  - [Aurobindo](#), [Glenmark](#) and [Sun](#) received FDA approval of AB-rated generic versions of Onglyza on July 31, 2023; Aurobindo and Glenmark are expected to launch their generics in the next week. Sun's launch plans for generic Onglyza are pending.
- Onglyza is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus